Form 4: Cidara Therapeutics Amends Insider Ownership Filings
Amendment to Statement of Changes in Beneficial Ownership
Cidara Therapeutics' President & CEO, Jeffrey Stein, filed an amended Form 4 to correct historical beneficial ownership reports, reflecting a 1-for-20 reverse stock split and clarifying transaction details.
Summary
- An amended Form 4 was filed by Jeffrey Stein, President & CEO and Director of Cidara Therapeutics, Inc. (CDTX).
- The amendment corrects several previously filed Form 4s from 2016, 2017, 2020, and 2021.
- All reported security numbers and prices have been adjusted to reflect a 1-for-20 reverse stock split that became effective on April 24, 2024.
- Corrections include rectifying an overstatement of beneficial ownership from the original May 23, 2016 filing.
- Multiple transactions on March 31, 2017, June 5, 2017, September 12, 2017, and November 10, 2020, were reclassified to reflect acquisitions by a trust rather than direct purchases by the Reporting Person.
- A December 10, 2020 transaction, initially reported as a holding, was corrected to reflect a gift of 658 shares, and the holdings received by a son were adjusted.
- A gift of 1,873 shares of securities by the Reporting Person to his sons on December 31, 2021, is detailed, with 937 shares acquired by a son. The Reporting Person disclaims beneficial ownership of shares held by his independent son.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While the need for multiple amendments indicates past reporting issues, the act of correcting these errors improves transparency and compliance, which is a positive for corporate governance. The underlying transactions are historical and do not reflect current company performance.
Positives
- Increased transparency and accuracy in insider beneficial ownership reporting for Cidara Therapeutics.
- Correction of historical errors provides a clearer and more reliable picture of management's holdings.
- Demonstrates compliance with SEC reporting requirements by proactively amending inaccurate filings.
Negatives
- The necessity of multiple amendments indicates past inaccuracies in reporting, which could suggest weaknesses in internal controls over financial reporting at the time of the original filings.
Risks
- Past erroneous filings could potentially lead to scrutiny from regulatory bodies, although the amendment addresses the issue.
- Investors may have previously made decisions based on inaccurate beneficial ownership data prior to these corrections.
Future Outlook
na
Industry Context
This filing is specific to insider transactions and beneficial ownership for Cidara Therapeutics and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Correction | Amendment of multiple Form 4 filings to accurately reflect beneficial ownership and transaction details, including reclassifying purchases by a trust versus direct purchases by the reporting person. | N/A (corrections to historical data) | Enhances transparency and accuracy of insider trading disclosures, improving corporate governance and investor confidence in reported ownership data. |
Related Party Transactions
- Gift of 658 shares of common stock on December 10, 2020, to a son.
- Gift of 1,873 shares of common stock (disposition from reporting person) and 937 shares (acquisition by son) on December 31, 2021, to sons, one of whom is economically dependent.
Stakeholder Impact
- Shareholders: Provides clearer and more accurate information regarding the beneficial ownership of a key executive, which can influence investment decisions and perceptions of corporate transparency.
- Regulatory Authorities: Demonstrates compliance with SEC regulations by correcting previously filed erroneous information.
Key Dates
| Date | Description |
|---|---|
| 05/23/2016 | Original Form 4 filing date, which erroneously overstated beneficial ownership. |
| 03/31/2017 | Transaction date for common stock disposition and acquisition by trust, originally misreported. |
| 04/04/2017 | Original Form 4 filing date for March 31, 2017 transaction. |
| 06/05/2017 | Transaction date for common stock disposition and acquisition by trust, originally misreported. |
| 06/07/2017 | Original Form 4 filing date for June 5, 2017 transaction. |
| 09/12/2017 | Transaction date for common stock disposition and acquisition by trust, originally misreported, and original Form 4 filing date. |
| 11/10/2020 | Transaction date for common stock disposition and acquisition by trust, originally misreported, and original Form 4 filing date. |
| 12/10/2020 | Transaction date for common stock disposition as a gift, originally misreported as a holding. |
| 03/19/2021 | Original Form 4 filing date for December 10, 2020 transaction. |
| 12/31/2021 | Transaction date for gift of securities to sons. |
| 04/24/2024 | Effective date of the 1-for-20 reverse stock split. |
| 01/07/2026 | Signature date of the amended Form 4. |
Keywords
Cidara Therapeutics, CDTX, Form 4, SEC filing, beneficial ownership, insider trading, stock split, amendment, Jeffrey Stein, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.